Triple-drug therapy with Goreisan, tranexamic acid and carbazochrome sodium sulfonate hydrate to prevent recurrence after chronic subdural haematoma surgery: a multicentre, randomised, controlled trial protocol Authors: Haruka Negishi, Koji Hirata, Hitoshi Aiyama, Keishi Fujita, Yoji Komatsu, Noriyuki Kato, Yasushi Shibata, Kyoji Tsuda, Tomosato Yamazaki, Masayuki Sato, Shinya Watanabe, Narushi Sugii, Takahiro Konishi, Bryan J Mathis, Tomohiro Ohigashi, Mitsuhiko Endo, Eiichi Ishikawa, Yuji Matsumaru, The Triple Study Investigators Published: 2025 ABSTRACT AbstractIntroductionChronic subdural haematoma (CSDH) is a common neurosurgical condition in older adults, with a recurrence rate of approximately 7.1–13% after burr-hole drainage. Although surgical adjuncts such as subdural drains and middle meningeal artery embolisation may reduce recurrence, these are not suitable for all patients. Pharmacological strategies, including tranexamic acid, Goreisan and carbazochrome sodium sulfonate hydrate, have shown potential, but high-level evidence remains lacking. A prior retrospective study suggested that a triple oral regimen combining these agents may reduce recurrence. This randomised controlled trial aims to evaluate its efficacy and safety.Methods and analysisThis is a prospective, multicentre, open-label, randomised controlled trial conducted across six hospitals in Ibaraki, Japan. A total of 180 patients undergoing first-time burr-hole surgery for CSDH will be randomised 1:1 to receive either triple therapy (Goreisan 7.5 g/day, carbazochrome sodium sulfonate hydrate 90 mg/day and tranexamic acid 750 mg/day for up to 90 days) or standard postoperative care. The primary outcome is recurrence requiring reoperation within 90 days. Secondary outcomes include time to recurrence and haematoma volume reduction on serial CT imaging. All analyses will follow the intention-to-treat principle, using logistic regression, Cox proportional hazards models and mixed-effects models.Ethics and disseminationWritten, informed consent will be obtained from all participants at each participating hospital by trained staff from that hospital. The trial protocol has been approved by the ethics committee of the University of Tsukuba Hospital (approval no. TCRB23-025) and the Institutional Review Boards of all participating centres. Study findings will be disseminated through presentations at scientific conferences and publications in peer-reviewed journals. A summary of the results will also be provided to participating institutions and made publicly available in accordance with the BMJ Open data sharing policy.Trial registration numberjRCTs031240007. STRENGTHS AND LIMITATIONS OF THIS STUDY This study is a multicentre, randomised, open-label, parallel-group trial with blinded assessment of imaging outcomes. This study is a multicentre, randomised, open-label, parallel-group trial with blinded assessment of imaging outcomes. Standardised surgical and postoperative management protocols are applied across all participating centres. Standardised surgical and postoperative management protocols are applied across all participating centres. Randomisation is stratified by key prognostic factors to reduce allocation bias. Randomisation is stratified by key prognostic factors to reduce allocation bias. The study is conducted exclusively in Japan, which may limit the external generalisability of the results. The study is conducted exclusively in Japan, which may limit the external generalisability of the results. Introduction Background and rationale Chronic subdural haematoma (CSDH) is becoming increasingly common, particularly in the elderly, and is projected to become the most frequently performed cranial neurosurgical procedure in ageing societies1 due to an ageing population and increasing usage of antithrombotic medication.2 The standard treatment for symptomatic CSDH is burr-hole drainage3 4; however, recurrence occurs in approximately 12.8% of cases,5 posing a major clinical challenge. Numerous studies have explored methods to reduce recurrence rates, including the placement of subdural drains,6 optimisation of drainage duration7 and minimisation of postoperative pneumocephalus.6 More recently, middle meningeal artery (MMA) embolisation has emerged as a promising adjunctive strategy for both treatment and prevention of CSDH recurrence.710 However, these surgical strategies may not be optimal in select populations. Pharmacological interventions, such as corticosteroids,11 atorvastatin,12 tranexamic acid and Goreisan (a Chinese traditional medicine compound),13 14 have also been investigated, but effectiveness remains uncertain. We previously conducted a retrospective study suggesting that a triple oral regimen of Goreisan, carbazochrome sodium sulfonate hydrate and tranexamic acid may reduce postoperative recurrence.13 Given the limitations of retrospective analyses, a robust randomised controlled trial (RCT) is needed to provide higher-level evidence. This study, therefore, aims to evaluate the efficacy and safety of this triple therapy in a multicentre, randomised, controlled, open-label trial. Objectives Objective To determine the efficacy and safety of Goreisan, carbazochrome sodium sulfonate hydrate and tranexamic acid administered after CSDH to prevent recurrence. Necessity Recurrence in 12.8% of CSDH cases is costly in reoperation as well as pain, recovery and quality-of-life reductions for patients. Data from this trial are expected to contribute towards useful prophylaxis against CSDH recurrence in clinical settings. Trial design This is a prospective, multicentre, open-label, randomised, parallel-group controlled trial to be conducted at six medical institutions in Ibaraki Prefecture, Japan. The trial aims to compare the efficacy of triple oral pharmacotherapy with standard postoperative care in preventing recurrence following burr-hole evacuation of CSDH. Methods: participants, interventions and outcomes Study setting The trial will take place at the University of Tsukuba Hospital, Hitachi General Hospital, Ibaraki Seinan Medical Center Hospital, Tsukuba Memorial Hospital, Mito Kyodo General Hospital and Mito Medical Center, which are all secondary-care or tertiary-care facilities in Ibaraki Prefecture, Japan. The trial is scheduled to run from 1 May 2024 to 31 March 2028. Eligibility criteria The following inclusion and exclusion criteria will be applied to all potential enrollees. Note that, as the trial is scheduled to be conducted at Japanese institutions, almost all patients are expected to be ethnically Japanese. There are no exclusion criteria for gender, orientation, religion or other demographic groups (unless explicitly listed). Inclusion criteria: Aged 18 years or older. Aged 18 years or older. Initial diagnosis of CSDH confirmed by CT or MRI. Initial diagnosis of CSDH confirmed by CT or MRI. Undergoing burr-hole drainage surgery for the first time. Undergoing burr-hole drainage surgery for the first time. Enrolment within 72 hours postoperatively. Enrolment within 72 hours postoperatively. Patients who are not scheduled to undergo MMA embolisation during the study. Patients who are not scheduled to undergo MMA embolisation during the study. Patients (or legal guardians) who have been fully informed about the study, fully understand it and have given written consent. Patients (or legal guardians) who have been fully informed about the study, fully understand it and have given written consent. Exclusion criteria: Patients who have undergone craniotomy and embolisation of the MMA. Patients who have undergone craniotomy and embolisation of the MMA. Cases of recurrent CSDH. Cases of recurrent CSDH. Patients who have undergone cerebrospinal fluid shunting. Patients who have undergone cerebrospinal fluid shunting. Patients with a history of hypersensitivity to this drug. Patients with a history of hypersensitivity to this drug. Patients who are taking any study drugs preoperatively. Patients who are taking any study drugs preoperatively. Patients with hereditary fructose intolerance. Patients with hereditary fructose intolerance. Patients in the acute phase of ischaemic vascular disease. Patients in the acute phase of ischaemic vascular disease. Patients undergoing treatment for deep vein thrombosis. Patients undergoing treatment for deep vein thrombosis. Consumptive coagulopathy/disseminated intravascular coagulopathy. Consumptive coagulopathy/disseminated intravascular coagulopathy. Predisposition to thrombosis. Predisposition to thrombosis. Patients on dialysis. Patients on dialysis. Patients who are pregnant. Patients who are pregnant. Patients who have received any other study or investigational drug within 3 months prior to the start of study drug administration. Patients who have received any other study or investigational drug within 3 months prior to the start of study drug administration. In cases where the principal investigator (or co-principal investigator) judges that the patient is unsuitable to enrol for any reason. In cases where the principal investigator (or co-principal investigator) judges that the patient is unsuitable to enrol for any reason. Ethics and dissemination Written, informed consent will be obtained from all participants at each participating hospital by trained staff from that hospital. The trial protocol has been approved by the ethics committee of the University of Tsukuba Hospital (approval no. TCRB23-025) and the Institutional Review Boards of all participating centres. Study findings will be disseminated through presentations at scientific conferences and publications in peer-reviewed journals. A summary of the results will also be provided to participating institutions and made publicly available in accordance with the BMJ Open data sharing policy. All procedures are conducted in accordance with the Declaration of Helsinki and the Clinical Research Act of Japan. Who will take informed consent University of Tsukuba trained medical staff and listed researchers approved by the Clinical Research Review Board of the Tsukuba Clinical Research and Development Organization (T-CReDO) will take informed consent. Written, informed consent will be obtained from all participants at each hospital by trained staff from that hospital (online supplemental file 1). Additional consent provisions for collection and use of participant data and biological specimens For participants enrolled at the University of Tsukuba, peripheral blood specimens will be collected at prespecified study time points and stored at −80°C for exploratory research. Planned analyses include RNA sequencing and ancillary biomarker investigations to elucidate molecular mechanisms underlying recurrence of CSDH and differential responses to the study interventions. At present, no secondary use beyond the exploratory analyses specified in this protocol is anticipated. Potential future use for related investigations may be considered in accordance with participant informed consent and applicable regulations. All specimens will be de-identified prior to storage, maintained under secure conditions and accessible only to authorised investigators at the University of Tsukuba. Any use extending beyond the current protocol will require prior ethics approval. Intervention description Participants in the intervention group will receive a combination of Goreisan: 7.5 g/day orally. Goreisan: 7.5 g/day orally. Carbazochrome sodium sulfonate hydrate: 90 mg/day orally. Carbazochrome sodium sulfonate hydrate: 90 mg/day orally. Tranexamic acid: 750 mg/day orally. Tranexamic acid: 750 mg/day orally. These medications will be administered for up to 90 days or until radiographic resolution of the haematoma. Control: standard postoperative care without oral pharmacologic prophylaxis; surgical techniques are not standardised across sites, but procedural details will be recorded for all patients. Figure 1 presents the study flowchart. Study flowchart. Participants in the intervention group received triple therapy (Goreisan, carbazochrome sodium sulfonate hydrate and tranexamic acid) for up to 90 days, while the control group received standard postoperative care without pharmacological prophylaxis. Explanation for the choice of the comparators The comparator is standard postoperative care following burr-hole evacuation, reflecting current practice and permitting estimation of the incremental benefit–risk profile of the triple-drug regimen. Criteria for discontinuing or modifying allocated interventions Discontinuation and dropout criteria: If a research participant declines to participate in the study or withdraws consent. If a research participant declines to participate in the study or withdraws consent. If a patient is found not to meet the eligibility requirements after registration. If a patient is found not to meet the eligibility requirements after registration. When adverse events make it difficult to continue the study. When adverse events make it difficult to continue the study. If the entire study is cancelled. If the entire study is cancelled. If the principal investigator determines it is appropriate to discontinue the study for any other reason. If the principal investigator determines it is appropriate to discontinue the study for any other reason. There are no provisions for modifying the allocated treatment groups. Strategies to improve adherence to interventions Interventions will be administered by qualified staff during hospital stays. The outpatients will self-administer the drugs or their family members (in cases where the outpatients are incapable) will administer the drugs for the outpatients. Relevant concomitant care permitted or prohibited during the trial Trombin is contraindicated for concomitant use. Haemocoagulase, batroxobin and coagulation factor preparations, such as Eptacog Alfa, are drugs that require caution when used in combination. Provisions for post-trial care There are no regulations regarding care after the trial. Outcomes Primary outcome:Recurrence or requirement for reoperation within 90 days of the initial surgery. Primary outcome: Recurrence or requirement for reoperation within 90 days of the initial surgery. Recurrence or requirement for reoperation within 90 days of the initial surgery. In cases of simultaneous surgery for bilateral CSDH: if recurrence or reoperation occurs in either side, it shall be recorded as recurrence. Regarding recurrence or reoperation: Recurrence or reoperation shall be defined as cases where reoperation is deemed necessary due to the recurrence of neurological abnormalities caused by a haematoma reaching a volume equivalent to that at the time of the initial surgery. Recurrence or reoperation shall be defined as cases where reoperation is deemed necessary due to the recurrence of neurological abnormalities caused by a haematoma reaching a volume equivalent to that at the time of the initial surgery. CSDHs newly occurring contralaterally during this trial shall not be considered recurrence but shall be registered as events. CSDHs newly occurring contralaterally during this trial shall not be considered recurrence but shall be registered as events. As a third-party assessment, one radiologist from another institution unknown to the assigned group will perform the imaging evaluation and determine whether non-recurrence or recurrence is appropriate. As a third-party assessment, one radiologist from another institution unknown to the assigned group will perform the imaging evaluation and determine whether non-recurrence or recurrence is appropriate. Secondary outcomes including exploratory biomarker analyses:Time to recurrence.Changes in haematoma volume assessed by CT on postoperative days 1, 10, 30, 60 and 90.Exploratory analyses will include RNA sequencing and gene expression profiling of markers such as AQP4, Janus kinases, interleukins and interferons from peripheral blood samples. Secondary outcomes including exploratory biomarker analyses: Time to recurrence. Time to recurrence. Changes in haematoma volume assessed by CT on postoperative days 1, 10, 30, 60 and 90. Changes in haematoma volume assessed by CT on postoperative days 1, 10, 30, 60 and 90. Exploratory analyses will include RNA sequencing and gene expression profiling of markers such as AQP4, Janus kinases, interleukins and interferons from peripheral blood samples. Exploratory analyses will include RNA sequencing and gene expression profiling of markers such as AQP4, Janus kinases, interleukins and interferons from peripheral blood samples. Other sociodemographic and clinical measures. Other sociodemographic and clinical measures. Participant timeline Figure 2 presents the schedule of enrolment, interventions and assessments. Study schedule of enrolment, interventions and assessments. aInformed consent and collection of patient background information are acceptable up to 72 hours postoperatively. bBlood tests include complete blood count (CBC), activated partial thromboplastine time (APTT), prothrombin time (PT), fibrinogen, D-dimer, aspartate aminotransferase (AST), alanine aminotransferase (ALT), γ-glutamyl transpeptidase (γ-GTP), total bilirubin, Na, K, Cl, C-reactive protein (CRP) and gene expression analysis (limited to cases at the University of Tsukuba). cData obtained within 2 weeks prior to enrolment may be used. dPre-enrolment data may be used. eIf no recurrence is observed, evaluation by day 30 ± 7 is mandatory. fIf the haematoma has resolved, further assessments may be omitted. Sample size (14) Based on preliminary retrospective data indicating a recurrence rate of 15%7 15 16 in the control group versus 2.5%13 in the intervention group, a total of 174 participants are required to achieve 80% power at a two-sided α level of 0.05 for Fisher’s exact test. To account for potential dropout or loss to follow-up, the target enrolment is set at 180 patients. Recruitment (15) Assignment of interventions: allocation Sequence generation Participants are to be randomly assigned to the treatment (oral therapy) or control (non-oral therapy) groups using a computer-generated allocation sequence, implemented through an electronic data capture (EDC) system. Randomisation is to be stratified by the presence or absence of bilateral lesions. Concealment mechanism Eligible patients will be randomised 1:1 using an EDC system (Alliance Clinical Research Supporting System (ACReSS)), stratified by the presence of bilateral CSDH. Due to the nature of the intervention, the study will be open-label; however, radiological assessments of haematoma volume and recurrence will be performed by blinded, independent reviewers. Implementation After registration, the trial physician will use ACReSS to assign patients and issue prescriptions as necessary. Assignment of interventions: blinding Who will be blinded This is an open-label trial. Outcome assessors for imaging endpoints are blinded to treatment allocation; participants and treating clinicians are not blinded. A blinded radiologist from another institution will perform the imaging evaluation and determine whether non-recurrence or recurrence is appropriate. Procedure for unblinding if needed None. Data collection and management Plans for assessment and collection of outcomes An EDC system (ACReSS) will be used to collect and assess all data from the study. Plans to promote participant retention and complete follow-up Registered participants will make regular outpatient visits. Data management Data collection will be conducted using electronic case reports via ACReSS and data entry will be performed by study investigators as appropriate during periodic evaluations. Data will be stored in an electronic database on a secure server. Queries will be issued by central monitoring in the event of data entry errors or missing values. Confidentiality All data and study-related documents will be handled in accordance with the University of Tsukuba Hospital regulations on the protection of personal information. Direct identifiers such as patient names and medical record numbers will be removed and replaced with subject identification codes. The correspondence table linking the codes to personal identifiers will be stored in a separate, secure file accessible only to the principal investigator. Clinical trial data will be recorded in a validated EDC system hosted on a secure, access-controlled institutional server. Source documents, including signed consent forms, will be stored in locked cabinets in restricted-access areas. Electronic files will be password-protected, and access to all data will be logged. Patient data will be used only for the purposes of this trial. Any future secondary use will require both prior ethics approval and participant written consent for that specific purpose. Study data will be retained for 5 years after publication of the trial results and then disposed of in accordance with institutional policy. Plans for collection, laboratory evaluation and storage of biological specimens for genetic or molecular analysis in this trial/future use Blood specimens collected at prespecified time points will be stored at −80°C at the University of Tsukuba, processed under Standard Operating Procedures for RNA sequencing and related biomarker analyses, retained for 10 years and disposed of per institutional policy. Access is limited to authorised investigators; linkage files are kept separately by the Principal Investigator. Statistical methods Statistical methods for primary and secondary outcomes Three statistical data sets will be used in the analyses: (a) a full analysis set (FAS), including all subjects without major protocol violations who underwent assessment of the primary endpoint after randomisation and took the study medication at least once in the intervention group; (b) a per-protocol set (PPS), including all subjects without violations of the eligibility criteria (selection and exclusion criteria) and who took the study medication for more than half of the planned period in the intervention group; and (c) a safety analysis set, including all subjects who were randomised. The efficacy analysis will be performed with the FAS and PPS. The safety analysis will be performed with the safety analysis set. The primary outcome will be analysed with a logistic regression model, including the group and the presence or absence of bilateral lesions. Among the secondary outcomes, time-to-event variables will be analysed with Cox proportional hazards models, including the group and the presence or absence of bilateral lesions. Among the secondary outcomes, longitudinal variables will be analysed with a mixed model for repeated measures (MMRM) analysis to detect changes in haematoma volume assessed by CT from baseline to 90 days. The MMRM analysis model will include the fixed effects of group, time point, group × time interaction, baseline measurements and the presence or absence of bilateral lesions. All statistical analyses will be conducted using SAS (version 9.4) or R software. Results will be deemed significant at p<0.05, and statistical tests will be conducted for two-tailed hypotheses. Interim analyses No interim analyses will be conducted. Methods for additional analyses No provisions exist for additional analyses. Methods in analysis to handle protocol non-adherence and any statistical methods to handle missing data In the MMRM analysis, there is no need for explicit imputation of missing values. For other analyses, neither modelling nor imputation of missing data will be performed. Plans to give access to the full protocol, participant-level data and statistical code The principal investigator and the implementing medical institution shall cooperate in the direct inspection of all trial-related records, such as source documents, during monitoring, audits and investigations by the certified clinical research review committee and regulatory authorities related to the trial. Outside access will not be permitted to participant-level data, but the full protocol and statistical details are published in the clinical journal and are freely available through that medium. Patient and public involvement Patients and/or the public were not involved in the design, conduct, reporting or dissemination plans of this research. This study was designed primarily as an investigator-initiated, multicentre, RCT conducted under the Clinical Research Act in Japan, which emphasises scientific and regulatory oversight. Although patients were not directly involved in the design stage, their perspectives were indirectly incorporated through prior feasibility studies and routine clinical feedback. Oversight and monitoring Composition of the coordinating centre and trial steering committee The T-CReDO is the primary authority under which clinical trials are conducted. As a registered coordinating centre, T-CReDO includes Institutional Review Board supervision, clinical trial supervisory/oversight bodies, regulatory compliance auditing, steering committees and advisory capacities. Composition of the data monitoring committee, its role and reporting structure Data management officer Koji Hirata, Hospital Lecturer, Department of Neurosurgery and Stroke and Cerebrovascular Diseases, University of Tsukuba Hospital. Koji Hirata, Hospital Lecturer, Department of Neurosurgery and Stroke and Cerebrovascular Diseases, University of Tsukuba Hospital. Statistical analysis officer(s) Biostatistics Division, Central Management Unit, Clinical Research Promotion Center, T-CReDO, University of Tsukuba. Biostatistics Division, Central Management Unit, Clinical Research Promotion Center, T-CReDO, University of Tsukuba. Monitoring officer Designated Monitoring Officer, T-CReDO, University of Tsukuba. Designated Monitoring Officer, T-CReDO, University of Tsukuba. Adverse event reporting and harms The investigational drug used in this trial is off-label for CSDH but its dosage and administration are equivalent to those for other diseases for which it is indicated. The investigational drug used in this trial is off-label for CSDH but its dosage and administration are equivalent to those for other diseases for which it is indicated. When administering the investigational drug, the potential risks and responses described in ‘Expected Adverse Reactions and Expected Problems’ will be taken into account in order to minimise risks. When administering the investigational drug, the potential risks and responses described in ‘Expected Adverse Reactions and Expected Problems’ will be taken into account in order to minimise risks. In the event of disease onset, appropriate examination and treatment will be administered. In the event of disease onset, appropriate examination and treatment will be administered. Information necessary for safe conduct of the trial will be collected and the study protocol modified if deemed medically necessary. Information necessary for safe conduct of the trial will be collected and the study protocol modified if deemed medically necessary. If the event forces the trial into the condition of ‘trial discontinuation or interruption’, trial discontinuation or suspension will be considered and judged by the investigator and clinical oversight committee. If the event forces the trial into the condition of ‘trial discontinuation or interruption’, trial discontinuation or suspension will be considered and judged by the investigator and clinical oversight committee. Even if the trial is discontinued or interrupted and the trial itself is terminated, routine medical care will continue and no direct disadvantage will be incurred by any participant. Even if the trial is discontinued or interrupted and the trial itself is terminated, routine medical care will continue and no direct disadvantage will be incurred by any participant. The postoperative courses of control participants will be monitored in the same manner as other participants. No disadvantages will be incurred. The postoperative courses of control participants will be monitored in the same manner as other participants. No disadvantages will be incurred. Frequency and plans for auditing trial conduct The central clinical monitoring authority located at the University of Tsukuba Hospital (T-CReDO) conducts constant surveillance and audits on trial conduct. Plans for communicating important protocol amendments to relevant parties (eg, trial participants, ethical committees) Important protocol modifications (eg, changes to eligibility criteria, outcomes, analyses) will be submitted for approval to the institutional review board. Approved amendments will also be updated in the trial registry and communicated to investigators and, where relevant, to participants. Dissemination plans Study findings will be disseminated through presentations at scientific conferences and publications in peer-reviewed journals. A summary of the results will also be provided to participating institutions and made publicly available in accordance with the BMJ Open data sharing policy. Authorship eligibility guidelines and any intended use of professional writers Authors will be selected based on the criteria of ICMJE guidelines and an advisory board will review and approve results before publication to ensure patient privacy. No professional writers, artificial intelligence ghostwriters or writing services will be used, and all manuscript preparation will be conducted ‘in house’ by qualified authors. Data sharing statement Deidentified individual participant data (including data dictionaries) will be made available upon reasonable request to the corresponding author after publication of the main results, in accordance with the data-sharing policy of the University of Tsukuba and relevant Japanese regulations. The study protocol, statistical analysis plan and informed consent form will also be accessible upon reasonable request. Data will be shared in a manner that ensures participant confidentiality and complies with ethical and legal requirements in Japan. Trial status The trial, now in V.1.0 as of 12 June 2025, is currently underway and actively recruiting patients. The trial will be conducted at each participating centre from 1 May 2024 to 31 March 2028. Supplementary material